NASDAQ:ANCN - ANCHIANO THERAP/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ANCHIANO THERAP/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.29 0.00 (0.00 %) (As of 02/16/2020 02:42 PM ET) Add Compare Today's Range$1.26Now: $1.29▼$1.3350-Day Range$1.28MA: $1.40▼$1.6052-Week Range$1.04Now: $1.29▼$9.44Volume24,348 shsAverage Volume19,519 shsMarket Capitalization$9.57 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:ANCN Previous Symbol CUSIPN/A CIKN/A WebN/A PhoneN/ADebt Debt-to-Equity Ratio0.11 Current Ratio1.60 Quick Ratio1.60Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($5.25) Net Income$-13,280,000.00 Net MarginsN/A Return on Equity-255.67% Return on Assets-136.55%Miscellaneous Employees19 Outstanding Shares7,420,000Market Cap$9.57 million Next Earnings Date3/23/2020 (Estimated) OptionableNot Optionable Receive ANCN News and Ratings via Email Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ANCN Rates by TradingView ANCHIANO THERAP/S (NASDAQ:ANCN) Frequently Asked Questions What is ANCHIANO THERAP/S's stock symbol? ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN." How were ANCHIANO THERAP/S's earnings last quarter? ANCHIANO THERAP/S (NASDAQ:ANCN) issued its quarterly earnings data on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.12. View ANCHIANO THERAP/S's Earnings History. When is ANCHIANO THERAP/S's next earnings date? ANCHIANO THERAP/S is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for ANCHIANO THERAP/S. What price target have analysts set for ANCN? 3 Wall Street analysts have issued 12-month target prices for ANCHIANO THERAP/S's stock. Their forecasts range from $12.00 to $16.00. On average, they anticipate ANCHIANO THERAP/S's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 985.3% from the stock's current price. View Analyst Price Targets for ANCHIANO THERAP/S. What is the consensus analysts' recommendation for ANCHIANO THERAP/S? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ANCHIANO THERAP/S. Has ANCHIANO THERAP/S been receiving favorable news coverage? Headlines about ANCN stock have trended neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ANCHIANO THERAP/S earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for ANCHIANO THERAP/S. Who are some of ANCHIANO THERAP/S's key competitors? Some companies that are related to ANCHIANO THERAP/S include Fibrocell Science (FCSC), Aerpio Pharmaceuticals (ARPO), AzurRx BioPharma (AZRX), Aptevo Therapeutics (APVO), Nemus Bioscience (NMUS), Aileron Therapeutics (ALRN), OHR Pharmaceutical (OHRP), Acerus Pharmaceuticals (TRLPF), Aytu Bioscience (AYTU), Novelion Therapeutics (NVLN), Novelion Therapeutics (NVLNF), Amarillo Biosciences (AMAR), Acerus Pharmaceuticals (ASPCF), Melinta Therapeutics (MLNT) and Sienna Biopharmaceuticals (SNNA). What other stocks do shareholders of ANCHIANO THERAP/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Cronos Group (CRON), CytomX Therapeutics (CTMX), Gilead Sciences (GILD), Huntington Bancshares (HBAN), Kiniksa Pharmaceuticals (KNSA), Methanex (MEOH), PacWest Bancorp (PACW) and People's United Financial (PBCT). Who are ANCHIANO THERAP/S's key executives? ANCHIANO THERAP/S's management team includes the folowing people: Dr. Frank G. Haluska, Pres, CEO & Director (Age 60)Mr. Jonathan Burgin, CFO & COO (Age 58)Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 53)Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 81)Dr. Michal Gilon Ohev-Zion, VP of R&D (Age 41) When did ANCHIANO THERAP/S IPO? (ANCN) raised $35 million in an initial public offering (IPO) on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. Who are ANCHIANO THERAP/S's major shareholders? ANCHIANO THERAP/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include Meitav Dash Investments Ltd. (5.01%). Which institutional investors are selling ANCHIANO THERAP/S stock? ANCN stock was sold by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd.. How do I buy shares of ANCHIANO THERAP/S? Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ANCHIANO THERAP/S's stock price today? One share of ANCN stock can currently be purchased for approximately $1.29. How big of a company is ANCHIANO THERAP/S? ANCHIANO THERAP/S has a market capitalization of $9.57 million. The company earns $-13,280,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.View Additional Information About ANCHIANO THERAP/S. MarketBeat Community Rating for ANCHIANO THERAP/S (NASDAQ ANCN)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 53 (Vote Outperform)Underperform Votes: 54 (Vote Underperform)Total Votes: 107MarketBeat's community ratings are surveys of what our community members think about ANCHIANO THERAP/S and other stocks. Vote "Outperform" if you believe ANCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANCN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2020 by MarketBeat.com StaffFeatured Article: P/E Growth (PEG)
